Ze'an Biopharmaceutical

Ze'an Biopharmaceutical (LTZ Therapeutics, 泽安生物) is a clinical-stage biotech founded in 2022 by CEO Jinze Li (Robert Li), built around what it calls a globally first-in-class "myeloid cell engager" platform, U-MCE™, targeting oncology and autoimmune disease . Its lead asset LTZ-301 is in Phase I trials at multiple US clinical centers — the FDA cleared its IND in early 2025 — with a second candidate, LTZ-232, heading toward its own IND . On the business side, 2025 was its breakout year for partnering: a July strategic deal with Eli Lilly on myeloid engager drugs for autoimmune disease (including tiered royalties), followed in November by a GSK collaboration on up to four first-in-class oncology candidates carrying a $50 million upfront payment . Funding has kept pace: an oversubscribed $40 million Series A+ in April 2025 backed by BlueRun Ventures, then a $38 million round in May 2026 led by GL Ventures with a sovereign wealth fund and existing holders including BlueRun, Boyu, 5Y Capital, and Shunwei — bringing cumulative funding to roughly $130 million; Qiming Venture Partners came in earlier, participating in the Pre-A round, leading Pre-A+, and adding in the A round .